Nathan John Robison, MD

Associate Professor of Clinical Pediatrics

Image of Nathan John Robison, MD
Is this your profile? Click to edit

Overview

After completing his residency and fellowship at Children’s Hospital Los Angeles, Dr. Robison completed an additional fellowship in Pediatric Neuro-Oncology at the Dana-Farber / Children’s Hospital Cancer Center in Boston. He served as clinical instructor at Harvard Medical School and attending staff in the Pediatric Neuro-Oncology Program at Dana Farber Cancer Institute and Boston Children’s Hospital from 2010 to 2013.

In April 2013 he joined the faculty of the University of Southern California Keck School of Medicine as assistant professor of pediatrics, and now serves as attending staff in the Pediatric Neuro-Oncology Program at Children’s Hospital Los Angeles.

Dr. Robison’s primary research focus is developing clinical trials that test new strategies in the treatment of children with brain tumors. Specific areas of interest include molecular targeted treatment of low-grade glioma, diffuse pontine glioma, and medulloblastoma; novel treatments targeting the tumor microenvironment, including antiangiogenic and immunomodulatory strategies; and neurofibromatosis.

Publications

  • Effective re-induction regimen for children with recurrent medulloblastoma. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae070.. View in PubMed
  • Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group. Neuro Oncol. 2024 03 04; 26(3):407-416.. View in PubMed
  • Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 2023 12 08; 25(12):2262-2272.. View in PubMed
  • An Exome Capture-Based RNA-Sequencing Assay for Genome-Wide Identification and Prioritization of Clinically Important Fusions in Pediatric Tumors. J Mol Diagn. 2024 02; 26(2):127-139.. View in PubMed
  • Addendum: Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget. 2023 May 19; 14:502.. View in PubMed
  • MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro Oncol. 2022 11 02; 24(11):1845-1856.. View in PubMed
  • Cardiac Function in Children and Young Adults Treated with MEK Inhibitors: A Retrospective Cohort Study. Pediatr Cardiol. 2022 Aug; 43(6):1223-1228.. View in PubMed
  • Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients. J Pediatr Hematol Oncol. 2021 11 01; 43(8):e1201-e1204.. View in PubMed
  • Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab037.. View in PubMed
  • NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.. View in PubMed